Physician profile
Jonathan E Vichosky
NPI 1023695202
$4,430.65
in general payments reported to CMS, 2019-2025
26 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $735 · 2023: $964 · 2024: $1,018 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.43 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,972.43 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.35 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Qol Medical, LLC | $277.19 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $277.07 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $256.02 | 2024-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $245.45 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $153.29 | 2024-2025 | Zenpep |
| Vivus LLC | $93.49 | 2024-2025 | Qsymia |
| Sandoz INC. | $84.36 | 2023-2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $75.43 | 2025 | Iqirvo |
| Ardelyx, INC. | $65.42 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $59.63 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $57.35 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $56.98 | 2023-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $51.43 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $36.82 | 2022-2023 | Sutab |
| Celltrion USA INC. | $36.30 | 2024-2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.15 | 2023-2024 | Cyltezo |
| Medtronic, INC. | $33.96 | 2025 | Interstim |
| Celgene Corporation | $27.86 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $26.69 | 2024 | |
| Genzyme Corporation | $23.85 | 2022 | |
| Exact Sciences Corporation | $22.32 | 2023 | |
| Gilead Sciences, INC. | $20.85 | 2025 | |
| Lilly USA, LLC | $16.09 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $13.87 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Vichosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.